This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense sourcing references. Topics showcase challenges and solutions of issues encountered, offering tremendous experience accumulated over many years of research that will be particularly useful to basic and bench scientists as well as clinicians as they continue discovering and developing new drugs and therapies.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
A complete, one-stop reference to real-world antiviral drug discovery and development
The field of antiviral drugs continues to evolve at a fast pace in response to new virus discoveries and development of viral resistance to existing therapies. This book provides case histories and arms both basic and industrial pharmaceutical researchers with practical tools to tackle the ongoing challenges of antiviral drug design, discovery, and development.
Written by leading authorities from academia and industry, Antiviral Drugs compiles information previously scattered across the literature into one complete, self-contained volume, unlike any other book on the subject. The authors draw on their own extensive research experience to present numerous case studies illustrating the full drug design process, from bench to clinic, with special emphasis on proven strategies for the development of drugs against all major viral infectious diseases, including HIV, HCV, RSV, influenza, HBV, and CMV.
Readers will find everything they need to analyze, understand, and apply discovery and development principles, including:
Coverage of newly approved antiviral drugs and compounds in clinical development
Emphasis on novel experimental molecules used to combat viral infections
Viral inhibitory mechanistic information
Clear examples for how to bring drugs from laboratory discovery to clinical trials
Effective examples and strategies of lead optimization yielding molecules of clinical value
Practical solutions for issues such as pharmacokinetics, viral resistance, and more
Key and specific references for readers wishing to explore the topics further
Wieslaw M. Kazmierski, PhD, has worked on novel HIV and HCV therapies in both small and large pharma settings in the last two decades, helping to advance molecules to clinical trials. Dr. Kazmierski has authored numerous peer reviewed publications and has been named a co-inventor on many patents. He has edited scientific books and had served on journal editorial boards.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.